Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, ...
MedPage Today on MSN
Trastuzumab Deruxtecan Scores Two Wins in HER2-Positive Early Breast Cancer
BERLIN -- The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in different ...
Alphamab Oncology (stock code: 9966.HK) announced that two latest clinical data on biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 for the treatment of primary platinum-refractory ...
Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, HER2-negative breast cancer patients. Sacituzumab tirumotecan significantly ...
Gedatolisib combined with fulvestrant, with or without palbociclib, significantly improved PFS in HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. The triplet regimen reduced ...
Learn about HER2+ breast cancer, its aggressive nature, and the latest treatments available in India. Explore the impact of ...
Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...
MedPage Today on MSN
For Your Patients: Next Steps If There Is Resistance to Endocrine Therapy
When cancer progresses on endocrine therapy, the next step is likely either a biopsy to gather tissue for testing or a liquid ...
Lilly's Verzenio prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment: Indianapolis Monday, October 20, 2025, 12:00 Hrs [IST] Eli Lilly and ...
Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about ...
Adding abemaciclib to endocrine therapy improved overall survival in patients with HR-positive, HER2-negative, node-positive, high-risk early breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback